AI-powered pharmaceutical solutions provider Partex has joined forces with Singapore's Experimental Drug Development Centre (EDDC) to accelerate the progress of new drug development programs.

The collaboration plans to utilize Partex's AI-driven technology to identify new indications with related clinical paths for EDDC's established assets. The companies also hope to integrate laboratory experimental data to train, build, and verify new AI models to speed up the drug discovery process. 

Partex is a digital pharma platform that leverages AI and real-world data (RWD) across the entire drug discovery and development value chain. Its proprietary AI/ML technology enables target identification, lead generation, preclinical evaluation, clinical trial design, and post-marketing surveillance. The company aims to use its algorithms to accelerate drug development timelines, reduce costs, and increase the probability of success.